Literature DB >> 28938652

Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis.

Alexey Surov1, Hans Jonas Meyer1, Andreas Wienke2.   

Abstract

The purpose of this meta-analysis was to provide clinical evidence regarding relationship between ADC and cellularity in different tumors based on large patient data. Medline library was screened for associations between ADC and cell count in different tumors up to September 2016. Only publications in English were extracted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) was used for the research. Overall, 39 publications with 1530 patients were included into the analysis. The following data were extracted from the literature: authors, year of publication, number of patients, tumor type, and correlation coefficients. The pooled correlation coefficient for all studies was ρ = -0.56 (95 % CI = [-0.62; -0.50]),. Correlation coefficients ranged from ρ =-0.25 (95 % CI = [-0.63; 0.12]) in lymphoma to ρ=-0.66 (95 % CI = [-0.85; -0.47]) in glioma. Other coefficients were as follows: ovarian cancer, ρ = -0.64 (95% CI = [-0.76; -0.52]); lung cancer, ρ = -0.63 (95 % CI = [-0.78; -0.48]); uterine cervical cancer, ρ = -0.57 (95 % CI = [-0.80; -0.34]); prostatic cancer, ρ = -0.56 (95 % CI = [-0.69; -0.42]); renal cell carcinoma, ρ = -0.53 (95 % CI = [-0.93; -0.13]); head and neck squamous cell carcinoma, ρ = -0.53 (95 % CI = [-0.74; -0.32]); breast cancer, ρ = -0.48 (95 % CI = [-0.74; -0.23]); and meningioma, ρ = -0.45 (95 % CI = [-0.73; -0.17]).

Entities:  

Keywords:  ADC; DWI; MRI; cellularity; tumor

Year:  2017        PMID: 28938652      PMCID: PMC5601748          DOI: 10.18632/oncotarget.17752

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Diffusion weighted imaging (DWI) is a magnetic resonance imaging (MRI) technique based on measure of water diffusion in tissues [1]. Beside diagnostic potential, DWI can distinguish malignant from benign lesions [2, 3]. As reported previously, malignant tumors showed lower apparent diffusion coefficient (ADC) values in comparison to benign lesions [2, 3]. According to the literature, DWI can also provide additional information about tissue microstructure [1, 4–6]. Experimental studies showed a strong association between ADC and cell count in vitro [4-6]. It has been shown that increase of cell density restricted water diffusion and decreased ADC [5, 6]. However, published data of clinical investigations were inconsistent. While some authors identified significant correlations between ADC and cellularity in different tumor, other did not [7-11]. Moreover, there was a wide spectrum of reported correlation coefficients ranging from 0.1 to -0.79 [7-12]. Furthermore, the number of investigated patients/tumors in most studies was up to 50 [7-12]. Only few reports analyzed relative large collectives ranging from 102 to 138 patients [13-16]. Therefore, the reported data cannot be considered as evident. Overall, these facts question the possibility to use ADC as a surrogate biomarker for cellularity in clinical practice. The purpose of this meta-analysis was to provide clinical evidence regarding relationship between ADC and cellularity in different tumors based on large patient data.

RESULTS

Overall, the pooled correlation coefficient for all studies (Figure 1) was ρ = −0.56, (95 % CI = [−0.62; −0.50]), heterogeneity τ2 = 0.02, (p < 0.00001), I2 = 67 %, test for overall effect Z = 18.01 (p < 0.00001).
Figure 1

Forest plots of correlation coefficients between ADCmean and cellularity in patients from all involved 39 studies

On the next step, correlation coefficients for every tumor entities were calculated. For this analysis, only data for primary tumors were acquired (Figure 2). The calculated correlation coefficients ranged from ρ = −0.25 (95 % CI = [−0.63; 0.12]) in lymphoma to ρ = −0.66 (95 % CI = [−0.85; −0.47]) in glioma. Other coefficients were as follows: ovarian cancer, ρ = −0.64 (95% CI = [−0.76; −0.52]); lung cancer, ρ = −0.63 (95 % CI = [−0.78; −0.48]); uterine cervical cancer, ρ = −0.57 (95 % CI = [−0.80; −0.34]); prostatic cancer, ρ = −0.56 (95 % CI = [−0.69; −0.42]); renal cell carcinoma, ρ = −0.53 (95 % CI = [−0.93; −0.13]); head and neck squamous cell carcinoma (HNSCC), ρ = −0.53 (95 % CI = [−0.74; −0.32]); breast cancer, ρ = −0.48 (95 % CI = [−0.74; −0.23]); meningioma, ρ = −0.45 (95 % CI = [−0.73; −0.17]).
Figure 2

Forest plots of correlation coefficients between ADCmean and cellularity in different primary tumors

DISCUSSION

The present analysis provides evidence regarding correlation between ADC, in particular ADCmean, and cellularity in different tumors based on a large sample. Previously, numerous studies investigated associations between ADC and cell density in several tumors [7-46]. Overall, most reports showed significant correlations between these parameters [7, 9, 15, 16, 21, 32, 33, 41, 43]. So, Woodhams et al. found a strong inverse correlation ( ρ = −0.75, p = 0.001) between ADC and cell count in mucinous breast carcinoma [43]. Based on the reported data, it has been postulated that DWI, namely ADC is an imaging tool to estimate tumor cellularity [43]. However, there were also reports, in which no significant correlations between ADC values and cell count were found [11, 38]. For example, in different lymphomas, the correlation coefficient between cell count and ADC was ρ = 0.1 (p = 0.58) [10]. Similar negative results were published for head and neck carcinoma (ρ = −0.418, p = 0.201) [39], meningioma ( ρ = −0.20, p = 0.164) [38], and breast cancer (ρ = 0.048, p = 0.812) [11]. Some previous reports attempted to explain their negative findings by small number of patients [37, 39]. However, another cause of the controversial results in the literature is possible. Presumably, different tumors may have also different associations between ADC and tumor cell count. Our results confirmed this assumption. As seen, ADC showed a moderate inverse correlation with cellularity in the general collective. However, this finding did not apply for each tumor entity, and, therefore, cannot be used in clinical practice. We found that the correlation ADC vs cellularity ranged significantly in different tumors. It was weak in lymphomas, weak-to-moderate in breast cancer and meningiomas, moderate in most investigated epithelial tumors, and strong in gliomas, ovarian cancer, and lung cancer. It is still unclear, why ADC correlates well with cell count in some tumors, whereas in other does not. Presumably, not only cell count, but also other histopathological features, such as extracellular matrix, nucleic areas, ratio stroma/parenchyma, and /or microvessel density may play a role here. In fact, some studies found statistically significant associations between nucleic size and ADC in several lesions [46, 47]. Overall, our findings suggest that ADC does not reflect cellularity in all tumors. Our analysis also identified another problem. There are no reports regarding associations between ADC and cellularity in most gastrointestinal tumors: esophageal cancer, gastric cancer, colorectal carcinoma, gastrointestinal stromal tumors, hepatocellular carcinoma, pancreatic carcinomas, and gall bladder cancer. Also in malignancies of cutis, such as malignant melanoma, no reports about ADC/cell count could be identified. Except renal cell carcinoma and prostatic cancer, no data exist for urological malignancies. In addition, several tumors involved into the present meta-analysis, for example, HNSCC, renal cell carcinoma, lung cancer, and lymphomas contained small number of patients. This relativizes the calculated results. Finally, for some tumors, such as pancreatic neuroendocrine carcinoma [41], soft tissue sarcomas [15], and thyroid cancer [37], only one report was published, respectively. Therefore, no evident data could be estimated for these entities. Clearly, further researches are needed to investigate possible associations between ADC and cellularity in these tumors. Thereafter, a similar meta-analysis is also needed to prove new data. In conclusion, different inverse correlations were identified between ADC and cell count in the analyzed tumors. ADC correlated strongly with cell count in gliomas, followed by ovarian cancer, and lung cancer. Therefore, in these tumors, ADC can be used as an imaging marker to estimate cellularity. Moderate inverse correlations were identified between ADC and cell count in prostatic cancer, renal cell carcinoma, uterine cervical cancer, and head/neck squamous cell carcinomas. Furthermore, weak-to-moderate correlations were found in breast cancer and meningioma. This finding relativizes the possibility of ADC use to predict cellularity in these tumors. Finally, weak correlation was identified in lymphomas. Therefore, ADC cannot be used as a cellularity biomarker in this entity. No evident data can be provided to date for other malignancies.

MATERIALS AND METHODS

Data acquisition and proving

MEDLINE library was screened for associations between ADC and cell count in different tumors up to September 2016. The following search words were used: “DWI or diffusion weighted imaging or diffusion-weighted imaging or ADC or apparent diffusion coefficient AND cellularity or cell density or cell count or cell number”. Only publications in English were extracted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) was used for the research [48]. After exclusion of duplicates, a total of 494 publications was identified. These reports were involved into the further analysis. For this work, only data regarding ADCmean derived from diffusion weighted imaging (DWI) were acquired. Papers which did not contain correlation coefficients between ADC and cell count were excluded. In addition, data retrieved from diffusion tensor imaging and other DWI parameters, such as D, ADCmax, and ADCmin were also excluded. Finally, we excluded experimental animals and in vitro studies. Overall, 455 publications were excluded. Therefore, the present analysis comprises 39 publications with 1530 patients [7-46]. The following data were extracted from the literature: authors, year of publication, number of patients, tumor type, and correlation coefficients. Most frequently, different breast, followed by several brain tumors, uterine sarcomas, uterine cervical cancer, prostatic cancer, and ovarian cancer were reported (Table 1). Other tumors were rarer.
Table 1

Patients involved into the study

Diagnosisn%
Different breast tumors40226.28
Different brain tumors31820.78
Uterine muscle sarcoma1348.76
Uterine cervical cancer1308.50
Prostatic cancer1197.78
Ovarian cancer1107.19
Lymphoma714.64
Lung cancer694.51
Renal cell carcinoma593.86
HNSCC483.14
Endometrial cancer301.96
Pancreatic neuroendocrine tumor181.18
Thyroid cancer140.92
Spinal epidural tumors80.52
Total1530100

HNSCC, head and neck squamous cell carcinoma

HNSCC, head and neck squamous cell carcinoma

Meta-analysis

The methodological quality of the 39 included studies was independently checked by two observers (A.S. and H.J.M.) using the Quality Assessment of Diagnostic Studies (QUADAS) instrument according to previous descriptions [49, 50]. The results of QUADAS proving are shown in Table 2.
Table 2

Methodological quality of the involved 39 studies according to the QUADAS criteria

Yes (%)No (%)Unclear (%)
Patient spectrum24 (61.54)8 (20.51)7 (17.95)
Selection criteria25 (64.10)10(25.64)4(10.26)
Reference standard39 (100)
Disease progression bias39 (100)
Partial verification bias39 (100)
Differential verification bias39 (100)
Incorporation bias39 (100)
Text details39 (100)
Reference standard details39 (100)
Text review details18 (46.15)8 (20.51)13 (33.33)
Diagnostic review bias18 (46.15)9 (23.08)12 (30.77)
Clinical review bias38 (97.44)1 (2.56)
Uninterpretable results38 (97.44)1 (2.56)
Withdrawals explained38 (97.44)1 (2.56)
Spearman's correlation coefficient was used to analyze associations between ADCmean and cell count. The reported Pearson correlation coefficients in some publications were converted into Spearman correlation coefficients as reported previously [51]. The meta-analysis was undertaken by using RevMan 5.3. Heterogeneity was calculated by means of the inconsistency index I2[52, 53]. In a subgroup analysis studies were stratified by tumor type. Furthermore, DerSimonian and Laird random-effects models with inverse-variance weights were used without any further correction [54].
  54 in total

1.  Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma.

Authors:  Natsuko Onishi; Shotaro Kanao; Masako Kataoka; Mami Iima; Rena Sakaguchi; Makiko Kawai; Tatsuki R Kataoka; Yoshiki Mikami; Masakazu Toi; Kaori Togashi
Journal:  J Magn Reson Imaging       Date:  2014-03-04       Impact factor: 4.813

2.  Simultaneous (18)F-FDG-PET/MRI: Associations between diffusion, glucose metabolism and histopathological parameters in patients with head and neck squamous cell carcinoma.

Authors:  Alexey Surov; Patrick Stumpp; Hans Jonas Meyer; Matthias Gawlitza; Anne-Kathrin Höhn; Andreas Boehm; Osama Sabri; Thomas Kahn; Sandra Purz
Journal:  Oral Oncol       Date:  2016-05-07       Impact factor: 5.337

3.  Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging.

Authors:  J Wang; S Takashima; F Takayama; S Kawakami; A Saito; T Matsushita; M Momose; T Ishiyama
Journal:  Radiology       Date:  2001-09       Impact factor: 11.105

4.  Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology.

Authors:  Daniel I Glazer; Elmira Hassanzadeh; Andriy Fedorov; Olutayo I Olubiyi; Shayna S Goldberger; Tobias Penzkofer; Trevor A Flood; Paul Masry; Robert V Mulkern; Michelle S Hirsch; Clare M Tempany; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2017-03

5.  Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics.

Authors:  Yi Wang; Zongming E Chen; Vahid Yaghmai; Paul Nikolaidis; Robert J McCarthy; Laura Merrick; Frank H Miller
Journal:  J Magn Reson Imaging       Date:  2011-05       Impact factor: 4.813

6.  Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity.

Authors:  Paul D Humphries; Neil J Sebire; Marilyn J Siegel; Øystein E Olsen
Journal:  Radiology       Date:  2007-10-19       Impact factor: 11.105

7.  Diffusion-weighted magnetic resonance imaging of uterine cervical cancer.

Authors:  Ying Liu; Renju Bai; Haoran Sun; Haidong Liu; Dehua Wang
Journal:  J Comput Assist Tomogr       Date:  2009 Nov-Dec       Impact factor: 1.826

8.  Diffusion-weighted MR imaging in laryngeal and hypopharyngeal carcinoma: association between apparent diffusion coefficient and histologic findings.

Authors:  Juliette P Driessen; Joana Caldas-Magalhaes; Luuk M Janssen; Frank A Pameijer; Nina Kooij; Chris H J Terhaard; Wilko Grolman; Marielle E P Philippens
Journal:  Radiology       Date:  2014-04-17       Impact factor: 11.105

9.  Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters.

Authors:  Alexey Surov; Sebastian Gottschling; Christian Mawrin; Julian Prell; Rolf Peter Spielmann; Andreas Wienke; Eckhard Fiedler
Journal:  Transl Oncol       Date:  2015-12       Impact factor: 4.243

10.  Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma.

Authors:  R F Barajas; J L Rubenstein; J S Chang; J Hwang; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-03       Impact factor: 4.966

View more
  85 in total

1.  Diffusion profiling of tumor volumes using a histogram approach can predict proliferation and further microarchitectural features in medulloblastoma.

Authors:  Stefan Schob; Anne Beeskow; Julia Dieckow; Hans-Jonas Meyer; Matthias Krause; Clara Frydrychowicz; Franz-Wolfgang Hirsch; Alexey Surov
Journal:  Childs Nerv Syst       Date:  2018-05-31       Impact factor: 1.475

Review 2.  [Diffusion-weighted imaging-diagnostic supplement or alternative to contrast agents in early detection of malignancies?]

Authors:  S Bickelhaupt; C Dreher; F König; K Deike-Hofmann; D Paech; H P Schlemmer; T A Kuder
Journal:  Radiologe       Date:  2019-06       Impact factor: 0.635

3.  Diffusion-weighted breast imaging.

Authors:  K Deike-Hofmann; T Kuder; F König; D Paech; C Dreher; S Delorme; H-P Schlemmer; S Bickelhaupt
Journal:  Radiologe       Date:  2018-11       Impact factor: 0.635

4.  Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI.

Authors:  Ashok J Theruvath; Florian Siedek; Anne M Muehe; Jordi Garcia-Diaz; Julian Kirchner; Ole Martin; Michael P Link; Sheri Spunt; Allison Pribnow; Jarrett Rosenberg; Ken Herrmann; Sergios Gatidis; Jürgen F Schäfer; Michael Moseley; Lale Umutlu; Heike E Daldrup-Link
Journal:  Radiology       Date:  2020-05-05       Impact factor: 11.105

5.  Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation.

Authors:  Yi-Hsiu Chung; Ching-Fang Yu; Shao-Chieh Chiu; Han Chiu; Shin-Ting Hsu; Ching-Rong Wu; Chung-Lin Yang; Ji-Hong Hong; Tzu-Chen Yen; Fang-Hsin Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-24       Impact factor: 9.236

6.  Histogram analysis derived from apparent diffusion coefficient (ADC) is more sensitive to reflect serological parameters in myositis than conventional ADC analysis.

Authors:  Hans Jonas Meyer; Alexander Emmer; Malte Kornhuber; Alexey Surov
Journal:  Br J Radiol       Date:  2018-02-20       Impact factor: 3.039

7.  Manual and semi-automated delineation of locally advanced rectal cancer subvolumes with diffusion-weighted MRI.

Authors:  Nathan Hearn; William Bugg; Anthony Chan; Dinesh Vignarajah; Katelyn Cahill; Daisy Atwell; Jim Lagopoulos; Myo Min
Journal:  Br J Radiol       Date:  2020-09-02       Impact factor: 3.039

8.  Differentiation between solitary fibrous tumors and schwannomas of the head and neck: an apparent diffusion coefficient histogram analysis.

Authors:  Natsuko Kunimatsu; Akira Kunimatsu; Koki Miura; Ichiro Mori; Shigeru Nawano
Journal:  Dentomaxillofac Radiol       Date:  2019-01-10       Impact factor: 2.419

9.  Histogram Analysis Parameters Derived from Conventional T1- and T2-Weighted Images Can Predict Different Histopathological Features Including Expression of Ki67, EGFR, VEGF, HIF-1α, and p53 and Cell Count in Head and Neck Squamous Cell Carcinoma.

Authors:  Hans Jonas Meyer; Leonard Leifels; Gordian Hamerla; Anne Kathrin Höhn; Alexey Surov
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

10.  Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.

Authors:  Marianne Schell; Irada Pflüger; Gianluca Brugnara; Fabian Isensee; Ulf Neuberger; Martha Foltyn; Tobias Kessler; Felix Sahm; Antje Wick; Martha Nowosielski; Sabine Heiland; Michael Weller; Michael Platten; Klaus H Maier-Hein; Andreas Von Deimling; Martin J Van Den Bent; Thierry Gorlia; Wolfgang Wick; Martin Bendszus; Philipp Kickingereder
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.